We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
Bogdan Cristian Dinu
Trastuzumab +\- Pertuzumab without chemo prolonging neoadjuvant therapy for six cycles .Radiotherapy after both supraclavicullar clearance posibile .Endocrine therapy related with imunochemistry notation after tumor resection.
I have a very similar case, Er, Pr weak positive, Ger2 +ve. Complete clinical response after ONLY 4 CYCLES AC. starting Taxanes next, I plan surgery before I start Herceptin. If complete pathological response, might omit herceptin!!
The patient should be considered stage IV (none regional node mets) and treated by anti her2 (Trastuzumab +/_ Pertuzumab) till progression.
Local treatment (surgery +/_ RT) may be considered according to the local response.
The same recommandation -like mohamad -also from me !
Her2/neu by FISH, PDL1 and BRCA 1/2, done or not?
her2 by FISH. What is the role of pdl1 in her2 positive breast cancer. Do you recommend surgery?
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.